|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
When this interface is disrupted, we note loss of stable dimer-dimer complex formation on the DNA, compromised <i>oriP</i>-containing plasmid replication in cells, and impaired recruitment of the MCM3 complex to the <i>oriP</i> Surface conservation analysis reveals that these residues are part of a larger conserved surface that may be critical for recruitment of replication machinery to the <i>oriP</i> Our results reveal a new region of EBNA1 critical for its activity and one that may be exploited by targeted small molecules to treat EBV-associated disease.<b>IMPORTANCE</b> Epstein-Barr virus (EBV) is a causative agent of various malignancies and may also contribute to autoimmune disease.
|
31142669 |
2019 |
|
Renal Cell Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
In this study, we demonstrated that polo-like kinase 1 (PLK1)-mediated MCM3 phosphorylation regulates proliferation and apoptosis in RCC.
|
31186514 |
2019 |
|
Hepatitis C
|
0.010 |
Biomarker
|
disease |
BEFREE |
The patients with hepatitis B virus or hepatitis C virus infection only were combined into the HCC-V group for further analysis.
|
30755830 |
2019 |
|
Ovarian Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two hub genes, MCM3 and GINS2, were significantly associated with worse overall survival of patients with OC.
|
31703725 |
2019 |
|
Adrenal Cortical Adenoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Specimens of 81 adrenocortical adenomas and 3 adrenocortical carcinomas were stained with antibodies against MCM-3, 5, 7 and Ki-67.
|
30842144 |
2019 |
|
Adrenocortical carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Specimens of 81 adrenocortical adenomas and 3 adrenocortical carcinomas were stained with antibodies against MCM-3, 5, 7 and Ki-67.
|
30842144 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
In this study, we demonstrated that polo-like kinase 1 (PLK1)-mediated MCM3 phosphorylation regulates proliferation and apoptosis in RCC.
|
31186514 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two hub genes, MCM3 and GINS2, were significantly associated with worse overall survival of patients with OC.
|
31703725 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
The Cancer Genome Atlas data mining in the University of Alabama interactive web resource for pathways associated with poor survival of patients with adrenocortical carcinoma revealed significant upregulation of genes involved in DNA damage and regulation of cell-cycle pathways, such as AURKA, AURKB, CDK1, CDK4, CDK6, PLK1, CHEK1, CHEK2, CDC7, BUB3, and MCM3 (P < .001-.05).
|
30413320 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two hub genes, MCM3 and GINS2, were significantly associated with worse overall survival of patients with OC.
|
31703725 |
2019 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
MCM3: A Novel Proliferation Marker in Oral Squamous Cell Carcinoma.
|
27258565 |
2018 |
|
Diabetic Nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we further examined the roles of SND p102 in diabetic nephropathy (DN)-induced glomerulosclerosis.
|
30150789 |
2018 |
|
Glomerulosclerosis (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study, we further examined the roles of SND p102 in diabetic nephropathy (DN)-induced glomerulosclerosis.
|
30150789 |
2018 |
|
Borderline ovarian tumour
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this investigation was to assess the staining pattern and immunolocalization of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors (BOTs).
|
28493257 |
2018 |
|
Arteriosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Three new peptides, P101 (FGKQGFFPDSVNKALY, 5.5 nM IC<sub>50</sub>), P102 (TLYALSHAVNSYFDVD, 6.8 nM), and P103 (LYYKEDKTSLSASAAS, 95 nM), were tested in an atherosclerosis model (<i>Apoe<sup>-/-</sup></i> mice on Western diet).
|
28087520 |
2017 |
|
Atherosclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Three new peptides, P101 (FGKQGFFPDSVNKALY, 5.5 nM IC<sub>50</sub>), P102 (TLYALSHAVNSYFDVD, 6.8 nM), and P103 (LYYKEDKTSLSASAAS, 95 nM), were tested in an atherosclerosis model (<i>Apoe<sup>-/-</sup></i> mice on Western diet).
|
28087520 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, immunohistochemical analysis of MCM3 protein levels in human prostate tissue specimens showed elevated expression in bone metastasis and advanced human prostate cancer tissue samples.
|
28424404 |
2017 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, immunohistochemical analysis of MCM3 protein levels in human prostate tissue specimens showed elevated expression in bone metastasis and advanced human prostate cancer tissue samples.
|
28424404 |
2017 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, immunohistochemical analysis of MCM3 protein levels in human prostate tissue specimens showed elevated expression in bone metastasis and advanced human prostate cancer tissue samples.
|
28424404 |
2017 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of MCM 2, MCM3 and MCM7 mRNA correlated with poor outcome and may be clinically useful molecular prognostic markers in glioma.
|
25046975 |
2014 |
|
Papillary thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MCM3 protein expression in follicular and classical variants of papillary thyroid carcinoma.
|
23821456 |
2014 |
|
Follicular Variant Thyroid Gland Papillary Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Using immunohistochemistry method, MCM3 protein expression levels were compared in FVPTC, classic variant of papillary thyroid carcinoma (CVPTC), and multi-nodular goiter (MNG) tissues in a group of 32 cases.
|
23821456 |
2014 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
MYB can up-regulate MCM3 (minichromosome maintenance 3) and MCM7 expression; PGR can suppress BCL2 (B-cell lymphoma 2) expression; MYC can inhibit TGFB2 (transforming growth factor, beta 2) expression.
|
23098454 |
2012 |
|
Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we showed the frequent deregulation of MCM2 and MCM3 expression in 7 MB cell lines and 31 clinical samples.
|
20661220 |
2010 |
|
Meningioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We found a significant increase in MCM2 (8 fold), MCM3 (5 fold), MCM4 (4 fold), MCM5 (4 fold), MCM6 (3 fold), and MCM7 (5 fold) expressions in meningiomas.
|
19877719 |
2010 |